Remove Biobanking Remove Clinical Trials Remove Containment Remove Genomics
article thumbnail

University of Melbourne reveals design of new infectious disease institute

Pharmaceutical Technology

The new AIID building will include a human infection challenge unit, high-containment facilities, a robotic biobanking facility, interview rooms, dry laboratories and spaces for community engagement and co-design work. It will be located at 766–780 Elizabeth Street and 213–223 Berkely Street in the Melbourne biomedical precinct.

article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. Fast forward to today and, while many large-scale genomics studies still lack the infrastructure and consent policies to enable recontact, this is starting to change. Giving participants something in return.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Generation of strong research dataset cohorts must begin with high-quality clinical samples. Partnerships and Establishing Research Cohorts.

article thumbnail

WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. PFIZER DISCLOSURE NOTICE: The information contained in this release is as of July 8, 2021. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Biogen Safe Harbor.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. There are different subtypes of heart failure that have different clinical presentations.”. Heart failure affects about 6.2